eLife

Reviewed Preprint
v1 • April 23, 2026
Not revised

For correspondence:
christophe.jagla@uca.fr
csarret@chu-clermontferrand.fr

* equal contribution

Competing interests: No competing interests declared

Funding: See page 21

Reviewing editor: Claude Desplan, New York University, United States

© 2026, Zmojdzian et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Drosophila ryanodine receptor gene triggers functional and developmental muscle properties and could be used to assess the impact of human *RYR1* mutations

Monika Zmojdzian[1,2,*], Teresa Jagla[1,*], Florian Cherik[2], Magda Dubinska-Magiera[3], Marta Migocka-Patrzalek[3], Malgorzata Daczewska[3], John Rendu[4], Krzysztof Jagla[1], Catherine Sarret[1,2]

[1]Institute of Genetics Reproduction and Development, INSERM U1103, CNRS UMR6293, Université Clermont Auvergne, Clermont-Ferrand, France • [2]Reference Centre for Neuromuscular Disorders, Department of Medical Genetics, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France • [3]Department of Animal Developmental Biology, Faculty of Biological Sciences, University of Wroclaw, Wroclaw, Poland • [4]Université Grenoble Alpes, INSERM U1216, CHU Grenoble Alpes, Grenoble Institute Neurosciences, Grenoble, France

eLife Assessment

This **important** paper provides novel information on the function of the Drosophila ryanodine receptor (RyR) during muscle development. The authors analyze the effects of a rare human mutation that causes myopathy that affects a conserved region of the gene. They present **compelling** evidence that this variant affects muscle function in flies. These results suggest that Drosophila can be used as a tool for screening additional variants.

[Editors' note: this paper was reviewed by *Review Commons*.]

https://doi.org/10.7554/eLife.111053.1.sa3

Abstract

The ryanodine receptor (RYR) genes encode evolutionarily conserved calcium release channels involved in a wide range of calcium-dependent biological processes. Here we show that the sole *Drosophila* RYR gene (*dRyR*) functions in differentiated somatic and cardiac muscle as well as in developing embryonic myotubes. In the larval body wall muscles, dRyR protein localizes at the SR membranes and *dRyR* knockdown adversely affects muscle contractility, suggesting its conserved role in calcium-triggered E-C coupling. After *dRyR* attenuation, sarcomere and mitochondrial patterns are severely impaired, showing *dRyR* involvement in structural muscle properties. However, *dRyR* is also prominently expressed and functionally required in growing embryonic muscles. *dRyR* loss of function leads to myotube growth defects and thin myofiber phenotypes, while its overexpression induces myofiber splitting. Given the structural and functional conservation of *dRyR*, we used *Drosophila* to test the impact of one human *RYR1* variant of unknown significance (VUS). Larvae carrying *p.Met4881Ile RYR1* VUS showed impaired mobility and altered structural muscle properties reminiscent of those seen in *dRyR* knockdown, thus indicating it is likely pathogenic. Overall, we show that *Drosophila dRyR* plays a conserved role in setting muscle contractility and structural muscle features. Our findings underline the still under-investigated role of *dRyR* as a promyogenic factor and provide a first example of the impact assessment of a human *RYR1* VUS in *Drosophila*.

Introduction

The calcium ion (Ca^{2+}) concentration gradient is known to be a crucial second messenger signal in all eukaryotic cells. The calcium release channels encoded by ryanodine receptor genes are essential to maintaining correct Ca^{2+} dynamics across biological membranes. RYR proteins are cellular sites of interactions with ryanodine, an alkaloid isolated from the stem wood of the plant *Ryania speciosa* (Jenden and Fairhurst, 1969) that was used for several decades as an insecticide. Because of its muscle-paralyzing effect in humans, ryanodine has been replaced by insect-specific derivatives that are non-toxic for mammals. Analysis of the RYR multi-domain structures and phylogenetic relations among different taxa yields a model suggesting that it evolved from inositol 1,4,5-trisphosphate receptor (IP_3R)-like ancestral Ca^{2+} release channels. The RYR activity is strictly controlled and may respond to the presence of ions (Ca^{2+}, Mg^{2+}, and Zn^{2+}), proteins (calmodulin (Cam) and FK-506 binding protein (FKBP12/12.6)), and small molecules such as ATP, caffeine, and ryanodine. The domain structure is highly conserved. For example, the SPIa kinase and ryanodine receptor (SPRY) domain shares high sequence identity between vertebrates and invertebrates and is engaged in protein-protein interactions with several protein families (Hadiatullah et al., 2022).

The number of RYR copies ranges across taxa. Mammalian genomes carry three RYR genes. For example, in humans, *RYR1*, *RYR2* and *RYR3* are located on chromosomes 19q13.2, 1q43 and 15q13.3-14, respectively. Non-mammalian vertebrates, such as *Xenopus laevis* and chicken, have two *RYR* copies (Ottini et al., 1996) while in a zebrafish genome, there are five genes: *RYR1a*, *RYR1b*, *RYR2a*, *RYR2b*, and *RYR3* displaying high similarity to other vertebrate RYR genes (Wu et al., 2011). The greater number of RYR genes in zebrafish than in mammals and birds is thought to result from teleost-specific whole-genome duplication (Howe et al., 2013; Postlethwait et al., 1998). In the invertebrates *Drosophila melanogaster*, *Caenorhabditis elegans*, live scallop (*Placopecten magellanicus*), and lobster (*Homarus americanus*), a single RYR gene has been identified (Hasan and Rosbash, 1992; Maryon et al., 1996; Murayama & Kurebayashi, 2011; Quinn et al., 1998, Xu et al., 2000). However, through alternative splicing, the single invertebrate RYR gene produces several isoforms, thus increasing the diversity of the available protein pool (De Mandal et al., 2019; George et al., 2007).

It is well known that RYR genes are expressed in muscle cells and play a crucial role in muscle contraction, which results from excitation-contraction (E-C) coupling, a series of events involving the conversion of electrical stimulus to Ca-dependent mechanical response. However, RYRs are also expressed in many other animal tissues including the central nervous system (Klatt Shaw et al., 2018; Q. Liu et al., 2005) and are involved in housekeeping functions in the cells of the adult organism and in developmental processes (Fill & Copello, 2002).

RYR1 mutations underlie an array of diseases including muscle-impairing central core disease (CCD), one of the most frequent congenital myopathies, and malignant hyperthermia susceptibility (MHS), characterized by severe reaction to anesthetics, excessive heat or exercise, which can be fatal. In addition, several *RYR2* mutations have also been implicated in cardiopathic catecholaminergic polymorphic ventricular tachycardia (CPVT) and arrhythmogenic right ventricular dysplasia of type 2 (ARVD2) (Lanner, 2012). Of the numerous mutations identified to date in RYR genes, most are missense mutations with single amino acid substitutions. However, several deletions, duplications and frame shift mutations have also been identified (Lanner, 2012).

Here, we analyze the phylogenetic origin, expression and function of the *Drosophila* dRyR gene. Our data show that *dRyR* is not only required for contractile properties of differentiated somatic and cardiac *Drosophila* muscle but also influences muscle structure and plays an instructive role in muscle development. Structural muscle changes in a *dRyR* loss-of-function context suggest its implication in age-associated muscle decline, while severe developmental muscle defects observed in *dRyR* mutant embryos provide insights into early-onset RYR-related myopathies. Considering extensive structural and functional *dRyR* conservation, we generated a *Drosophila* model of one undiagnosed human *RYR1* variant mutation (*p.M4881Ile*) and found that it negatively impacted muscle structure and function, making it likely pathogenic. We report a detailed functional

analysis of *dRyR*. Our findings pinpoint the under-investigated role of *dRyR* in embryonic muscle development and demonstrate that *Drosophila* could be used for assessing impacts of human *RYR1* variant mutations of unknown significance.

Results

Drosophila dRyR belongs to the RYR gene family and shows conserved somatic and cardiac muscle-associated expression and function

dRyR is the sole RYR gene family member in *Drosophila*. We applied the maximum likelihood method and the Kimura 2-parameter model (Kimura, 1980) to infer the evolutionary history of *dRyR*. Based on evolutionary distance studies, *RYR2* is the most ancient of three human RYR genes (Ding et al., 2017) and shows the highest sequence homology with *Drosophila dRyR*. We compared sequences of *RYR2* from selected mammalian and non-mammalian vertebrates with the sequence of single invertebrate RYR, including fruit fly *dRyR* to illustrate its phylogenetic origin (Fig. 1A) (Ding et al., 2017; Mackrill, 2012; McKay & Griswold, 2014; Takeshima et al., 1994). Evolutionary analyses were conducted in MEGA X (Kumar et al., 2018; Stecher et al., 2020). We observed that single invertebrate RYR genes, here from *Drosophila* and *C. elegans*, clustered into a separate branch connected to the vertebrate *RYR2* branch that clustered 100% (Fig. 1A). The vertebrate *RYR2* branch was then subdivided clonally from *Xenopus* through zebrafish, chick and mouse to human. All clonal branches in vertebrates clustered 100% (Fig. 1A), indicating that *RYR2* genes are closely related and most probably evolved from a single invertebrate RYR.

Expression of RYR genes in vertebrates has been extensively studied and described in various excitable cells including skeletal and cardiac muscles and neurons, and in non-excitable cells such as pancreatic beta cells and lymphocytes (Rossi & Sorrentino, 2002). By contrast, in spite of early works by Hasan and Rosbash (1992) and Sullivan et al., (2000) no systematic analyses have yet been performed to assess the developmental expression pattern of the sole *Drosophila dRyR* gene.

We first tested the expression of *dRYR* at protein level. In differentiated body wall muscle of 3rd instar larva (Fig. 1B,C) *dRyR* was detected in a discrete striated pattern (Fig. 1B), which in a zoom view revealed highly ordered punctate dRyR protein localization in close vicinity to discs large (Dlg)-positive T-tubules (Fig. 1C and scheme in Fig. 1D). Thus, in *Drosophila* muscle, like in vertebrates, dRyR localizes at the T-tubule interface, a sub-cellular localization consistent with its calcium release role at SR and E-C coupling function during muscle contraction.

We also assessed muscle-associated expression of *dRyR* transcripts (Fig. S1). Of ten *dRyR* transcript isoforms, all coded for proteins of similar amino acid (aa) length, ranging from 5113 to 5134 aa and molecular weight about 580 kDa (*http://flybase.org/reports/FBgn0011286.htm*). To test *dRyR* isoform expression, we applied the FISH-HCR technique (Choi et al., 2016) and four probes targeting alternative exons 10, 11, 22 and 23 (Fig. S1A). In this setup we detected the expression of the A,B,F,G,H,J isoforms with the *dRyR* Ex10 probe, A,B,C,D,E,I isoforms with the Ex11 probe, A,B,C,D,E,F,G isoforms with the Ex22 probe and H,I,J isoforms with the Ex23 probe (Fig. S1A).

FISH-HCR experiments performed on differentiated 3rd instar larval muscles revealed muscle-associated specific signals with all four probes (Fig. S1B-E'). *dRyR* transcripts were detected at the periphery of nuclei, in the sarcoplasm and in a repeated striated pattern following sarcomeres. Similar signals observed with the four probes indicated that at least the isoforms A and B that are commonly targeted by the Ex10, Ex11 and Ex22 probes and one of the isoforms H,I or J targeted by the Ex23 probe were present in the functional body wall muscle. We could not, however, rule out the possibility that most or even all *dRyR* isoforms were expressed in the differentiated body wall muscles. Supporting this, we note that nine out of ten *dRyR* isoforms (isoform I being an exception) share the same transcription start site, suggesting that a common core promoter regulates their expression.



Figure 1. Phylogenetic origin of dRyR, its body wall muscle associated expression and role in locomotion.

(A) Evolutionary analysis by the maximum likelihood method of ryanodine receptor genes (RYR) from different taxa. The tree with the highest log likelihood (−95718.65) is shown. The percentage of trees in which the associated taxa clustered is shown next to the branches. (B) A wide view (upper panels) and a zoomed view (lower panels) of ventral VL3 larval muscle stained for dRyR (green) and Dlg (red) that labels T-tubules. (C) A high-magnification view showing dRyR dots at the interface of T-tubules (arrows). (D) Scheme presenting subcellular location of dRyR receptor at the sarcoplasmic reticulum (SR) membrane in a close vicinity of T-tubules. The dotted line refers to the optical level of confocal view in (C). (E-G) Larval muscle targeted *dRyR* knockdown (C57>dRyRRNAi) leads to a marked decline in muscle performance compared to control (C57>mCherryRNAi). Three muscle performance tests were applied: (E) righting test, (F) motility test, and (G) locomotor test. Overexpression of *dRyR* in larval muscle (C57>dRyR) impacts muscle performance measured by the locomotor and motility tests (F, G). Scale bar: 20 µm. All statistical analyses were performed using Prism. The one-way ANOVA test was used for comparisons of datasets. Bar plot represent the mean and the standard deviation. On the figures, statistical comparisons of sample vs control are indicated as ****: $P \leq 0.0001$; ***: $P \leq 0.001$; **: $P \leq 0.01$; *: $P \leq 0.05$; ns > 0.05.

Detected muscle-associated expression of *dRyR* prompted us to test its involvement in muscle contraction and larva mobility. We observed that muscle-targeted attenuation of *dRyR* expression resulted in reduced muscle performance with a significantly longer time required for larvae to switch from the dorsal to the ventral position (Fig. 1E – righting test) and a reduced number of muscle contraction waves compared to control recorded in 1 minute (Fig. 1F – motility test).

Finally, *dRyR-RNAi* larvae crawled inefficiently and were unable to move over a longer distance (Fig. 1G – locomotor test). In parallel, overexpressing *dRyR* in larval muscles also impaired muscle function, with fewer contraction waves in 1 minute compared to control and a slower locomotion (Fig. 1F,G), while the time required to switch from the dorsal to the ventral position remained unchanged (Fig. 1E).

Altogether, our data extend previous observations of affected muscle contractility in RyR mutants (Sullivan et al., 2000) and suggest that *Drosophila dRyR*, like its vertebrate counterparts, ensures correct muscle function, likely acting as a sarcoplasmic reticulum (SR) calcium release channel essential for muscle contraction and E-C coupling.

Given that vertebrate RYR genes (*RYR2* in humans) also play an instrumental role in cardiac muscle function, we sought to determine whether dRyR protein could be detected in the fly heart and whether it could influence heartbeat variables. In the adult *Drosophila* heart, dRyR protein was detected predominantly in the circular muscle fibers ensuring cardiac contractions (Fig. 2A-A'''), which appear structurally affected (Fig. 2C, E) in a heart-specific *dRyR RNAi* context (Hand>dRyR RNAi). Consistent with this, heart-targeted attenuation of *dRyR* resulted in an abnormal M-mode heart profile (Fig. 2B,D) associated with a longer heart period (Fig. 2F) and a slow heart rate (Fig. 2G), with significantly increased diastolic interval (Fig. 2H). Attenuation of cardiac *dRyR* expression also led to arrhythmic heartbeat (Fig. 2J), increased systolic diameter (Fig. 2K) and reduced fractional shortening (Fig. 2M). As the diastolic diameter remained unchanged, we conclude that cardiac dRyR knockdown affects cardiac performance without causing dilated cardiomyopathy. In contrast to dRyR-RNAi, increasing *dRyR* cardiac expression had only a minor influence on cardiac variables (Fig. 2F-M) with increased systolic diameter (Fig. 2K) but no effect on cardiac contractility (Fig. 2M). Overall, observed *dRyR* loss-of-function adult fly heart phenotypes with a slow heart rate and increased arrhythmia correlate with impaired cardiac function in RyR mutant larvae (Sullivan et al., 2000). We hypothesize that dRyR RNAi-induced impairment of Ca2+ homeostasis could contribute to cardiac aging, for which Drosophila is a recognized model (Nishimura et al., 2011).

In view of the reduced motility of 3rd instar larva with the attenuated *dRyR* (Fig. 1E-G) we examined whether structural properties of body wall muscles were adversely affected. We first found that muscle-targeted attenuation of *dRyR* (C57>dRyR RNAi) led to a significantly reduced larva body length (Fig. 3B, Q) compared to control (Fig. 3A, Q, an observation that correlates with previously observed (Sullivan et al., 2000) reduced body size of *dRyR*^{16} mutant larvae. Though to a lesser extent, the overexpression of *dRyR* in body wall muscles also impacted larva length (Fig. 3D, Q). These changes in larva size in loss and gain of *dRyR* function correlated with a reduced longitudinal muscle length (Fig. 3 E-H, R), which in turn correlated with shortening of Kettin/D-Titin-labelled sarcomeres (Fig.3 I-L, T) and reduced number of myonuclei (Fig.3 E-H, S). Because RYR-mediated calcium homeostasis involves dynamic interactions between the sites of calcium release from the SR and calcium uptake by the mitochondria (Li et al., 2025) we examined whether in *Drosophila dRyR* loss and/or *dRyR* gain of function could adversely affect mitochondria pattern in the larval muscles. We noted that the I band-associated striated mitochondria pattern was lost in the C57>dRyR RNAi context (Fig. S2 B) and appeared irregular when *dRyR* was overexpressed in muscles (Fig. S2 D) compared to the wild-type larval muscles (Fig. S2A, B, E).

Both muscle-targeted attenuation and gain of *dRyR* function led not only to impaired muscle functions but also to overall reduction of muscle size and myofibrillar disarray associated with a downsizing of sarcomeres and mitochondrial mismatch. Altered structural muscle features observed in *dRyR*-attenuated *Drosophila* larvae are reminiscent of myofibrillar and mitochondrial pattern defects reported in mice harboring a pathogenic *RYR1* mutation (Elbaz et al., 2019).



Figure S1. **dRyR transcript expression in larval muscles.**

(A) Exon/intron organization of *dRyR* isoforms. FISH-HCR probes and targeted alternative exons are indicated by boxes with a color code. (B-E) Confocal views of *dRyR* transcript patterns in VL3 larval muscles revealed with FISH-HCR probes (white). Identities of the FISH-HCR probes and targeted *dRyR* isoforms are indicated above panels. Note highly similar subcellular distribution of different *dRyR* transcripts. (D') Exon11 FISH-HCR (white) with nuclear DAPI staining (blue). (E') Exon23 FISH-HCR (white) with phalloidin staining (red) to reveal sarcomeric pattern. Scale bar: 20 μm.



Figure 2. **dRyR is expressed in the heart tube and is required for correct heartbeat.**

(A-A‴) Adult heart tube labeled for dRyR (green) and actin (red). (A′, A′′′) Zoomed views revealing *dRyR* expression in circular fibers. (B,D) M-modes of control Hand/+ (B) and Hand>dRyR RNAi (D) contexts showing a slow heart rate induced by *dRyR* attenuation. Compared with control (C), circular fibers in Hand>dRyR RNAi (E) context showed a fuzzy pattern suggesting an affected sarcomeric organisation. (F-M) Heartbeat variables in cardiac *dRyR* knockdown (Hand>dRyR RNAi) and cardiac *dRyR* overexpression contexts (Hand>dRyR). Scale bar: 50 µm in A, A′′; 10 µm in A′, A′′′, C, E. All statistical analyses were performed using Prism. The one-way ANOVA test was used for comparisons of datasets. Bar plot represent the mean and the standard deviation. On the figures, statistical comparisons of sample vs control are indicated as ****: $P \leq 0.0001$ *: $P \leq 0.05$; ns > 0.05.



Figure 3. **Muscle targeted dRyR loss and gain of function impacts body size and structural muscle properties.**

(A-D) General views of 3rd instar larva in control (A, C), muscle-targeted *dRyR* attenuation (B) or overexpression (D). (E-H) Representative VL3 and VL4 ventral longitudinal muscle views from age-matched 3rd instar larvae in control (E, G), C57>dRyR RNAi (F) and C57>dRyR (H) contexts. Muscle fibers and nuclei were revealed with phalloidin (red) and DAPI (blue), respectively. (I-L) Zoomed views of VL3 muscles of control (I, K), C57>dRyR RNAi (J) and C57>dRyR (L) larvae triple stained for phalloidin (red), DAPI (blue) and Kettin/D-Titin (green). (M-P) Z band profiles (Kettin signal intensity plot) from zoomed views of VL3 muscles presented in (I-L). (Q)Statistical representation of 3rd instar larva length. (R-T) Statistical representation of VL3 muscle characteristics: (R)VL3 muscle length; (S) number of nuclei and (T) sarcomere size. Scale bar: 1 mm in A-C; 50 µm in D-F; 20 µm in G-I. Bar plots represent the mean and the standard deviation. All statistical analyses were performed using Prism. The one-way ANOVA test was used for comparisons of datasets. Bar plot represent the mean and the standard deviation. On the figures, statistical comparisons of sample vs control are indicated as ****: P ≤ 0.0001; ***: P ≤ 0.001; **: P ≤ 0.01; *: P ≤ 0.05; ns > 0.05.



Figure S2. **dRyR is required for correct mitochondria pattern.**

(A-D) Zoomed views of a 3rd instar VL3 muscle in control (A, C), muscle-targeted dRyR attenuation (B) or overexpression (D) stained for ATP5 to reveal mitochondria pattern. (E) Statistical representation of ATP5 staining area in control, C57>dRyR RNAi and C57>dRyR contexts. “% of total” means the percentage of the measured muscle area that is positive for ATP5a staining. Scale bar: 20 µm. All statistical analyses were performed using Prism. The one-way ANOVA test was used for comparisons of datasets. Bar plot represent the mean and the standard deviation. On the figures, statistical comparisons of sample vs control are indicated as; ***: $P \leq 0.001$.

dRyR is expressed during embryonic muscle development and is required for correct myogenic differentiation

Previous reports provide evidence that RYR-dependent elevation of intracellular calcium promotes late steps of myogenic differentiation and in particular fusion of myoblasts to myotubes (Eigler et al., 2021; Sinha et al., 2022). In parallel, a recent study on RYR1-depleted primary myoblasts revealed the calcium-independent inhibitory role of RYR1 in myogenic differentiation (Tourel et al., 2025). To further explore myogenic roles of RYRs, we tested *dRyR* expression and function during embryonic development.

Sullivan et al. (2000) reported embryonic *dRyR* transcript expression in body wall and visceral muscle precursors. Here, we tested dRyR protein expression and found that it was prominently expressed in the mesodermal derivatives in embryos. We detected dRyR protein in the developing visceral, somatic and cardiac muscle cells (Fig. 4). Regarding body wall muscles, dRyR could be detected in the somatic muscle precursors starting from embryonic stage 12 (Fig. 4A, A'), accumulated in the growing myotubes at mid-stage embryos (Fig. 4B, B') and continued to be expressed in the developing muscle fibers at later embryonic stages (Fig. 4C-D'). At embryonic stage 16, dRyR protein was distributed in a discrete granular pattern within the cytoplasm of myofibers and appeared excluded from the myonuclei (Fig. 4D,D'). Thus, dRyR protein was detected from the early phase of myogenic differentiation that encompasses specification of muscle founders and first myoblast fusion events and continues during the second phase of fusion and myofiber growth and maturation. We also applied HCR-FISH to test *dRyR* transcript isoform expression in the developing somatic muscle (Fig. S3). We found that *dRyR* A, B, F and G isoforms harboring alternative exons 10 and 22 were actively transcribed in the developing muscle, whereas the remaining *dRyR* isoforms were barely detected (Fig. S3).

Previous analyses (Sullivan et al., 2000) showed that muscle contraction was compromised in larvae carrying a hypomorphic $dRyR^{16}$ mutant allele. *dRyR* mutant larvae were also smaller in size and died before the pupation stage. However, whether *dRyR* embryonic expression has a functional impact on larval muscle development has not yet been assessed. Accordingly, we analyzed embryonic muscle pattern in late-stage $dRyR^{16}$ mutant embryos (Fig. 5). We observed a wide range of developmental somatic muscle defects with predominant phenotype of thin myofibers present in 64% of abdominal A2-A5 hemisegments and more severely sphere-shaped (arrowheads in Fig. 5B) or missing myofibers (asterisks in Fig. 5B) observed in 25% of hemisegments. In addition, in 10% of hemisegments with *dRyR* loss of function led to supernumerary lateral transverse (LT) muscles (arrows in Fig. 5B), a phenotype that could arise from LT muscle splitting (Bertin et al., 2021). Predominant thin/misshaped/missing myofiber phenotype in a *dRyR* loss-of-function context suggests a pro-myogenic role during development. To further characterize the role of dRyR during myogenesis, we analyzed embryonic LT muscle phenotypes in LT-targeted *dRyR* attenuation and gain-of-function contexts (Fig. 5C-E). Like in $dRyR^{16}$ mutant embryos, *dRyR* RNAi knockdown in LT muscles resulted in thin and/or misshaped LT muscles (Fig. 5D, H) observed in 88% of hemisegments and in rare cases of LT splitting, found in 8% of hemisegments (Fig. 5D, H). We noted no loss of LT muscles in *dRyR* RNAi embryos. Consistent with the promyogenic role of *dRyR*, LT-targeted overexpression of *dRyR* appears to promote LT splitting phenotype (Fig. 5E, H) found in 18% of hemisegments. Calmodulin (Cam is the major calcium dependent RYR regulator. The Ca2+-bound Cam at high calcium levels acts as RYR inhibitor (Fruen et al., 2003). We thus tested effects of Cam attenuation in LTs and found that it results in a dRyR overexpression-like phenotype (Fig. 5F, H). This suggests that during myogenesis Cam is present mainly in a calcium-bound form that represses dRyR. Another major regulator of calcium homeostasis, the endoplasmic reticulum calcium pump SERCA is required to maintain a high calcium levels in the ER lumen (Suisse & Treissman, 2019). To test its role in myogenesis we analysed Lms>SERCA RNAi embryos. We observe that SERCA-depleted LT muscles display growth defects with predominant thin myofiber phenotype (Fig. 5G, H) also observed in Lms>dRyR RNAi context (Fig. 5D, H). Thus, both dRyR-regulated cytosolic and SERCA-regulated ER lumen calcium levels are required to promote muscle development.



Figure 4. **Developmental dRyR protein pattern in embryos.**

(A-A′) lateral view of a stage 12 embryo. dRyR (green) could be detected in the somatic and visceral muscle precursors (arrows in A) also revealed by Actin (red) (A′). (B-C′) dorso-lateral views of stage 14 (B,B′) and stage 16 (C,C′) embryos. dRyR accumulates in body wall muscle precursors (arrows in B and C) and in visceral muscle of the midgut (arrowhead in B) and in the dorsally aligned cardioblasts (double-head arrow in C). (D,D′) Subcellular dRyR pattern in ventral muscle precursors at embryonic stage 16. Note granular cytoplasmic distribution of dRyR. Scale bar: 50 μm.



Figure S3. Embryonic expression of dRyR transcript isoforms.

(A) Exon/intron organization of *dRyR* isoforms. Blue, green, brown and red boxes indicate alternative exons 10, 11, 22 and 23 (FISH-HCR probes). (B-E) Representative views of stage 13 and stage 16 embryos stained for four FISH-HCR probes (white/green) and actin (red) to reveal somatic muscles. Note that Ex10 and Ex22 probes consistently labeled *dRyR* transcript isoforms listed at the top of panels that accumulate in the developing muscle precursors. No or only faint *dRyR* expression was detected with Ex11 and Ex23 probes. Scale bar: 50 µm.



Figure 5. dRyR is required for correct embryonic muscle development.

(A, B) ventro-lateral views of stage 16 embryos stained for actin to reveal embryonic muscle pattern in wild-type (A) and in homozygous *dRyR*^{16} mutant embryo (B). Note a wide range of developmental muscle defects that could be observed in *dRyR* loss-of-function context. Asterisks in B pinpoint muscle fiber loss, arrowheads indicate the myofibers that failed to extend and remained as myospheres and a series of arrows point to supernumerary lateral transverse myofibers (6 instead of 4). (C-E) Effects of lateral transverse (LT) muscle-targeted attenuation (D) and overexpression (E) of *dRyR*. LT muscles were revealed by targeted expression of LifeActinGFP (LA) transgene using LT-specific Lms-GAL4 driver. (C) Four LT muscles (arrows) are seen in a control Lms>LA;LacZ context. (D) dRyRRNAi attenuation led to misshaped thin LTs (arrowheads) – major phenotype and to an occasional LT muscle split phenotype (6 LTs indicated by arrows). (E) LT targeted overexpression of *dRyR* resulted mainly in LT muscle splitting (arrows). (F) Cam attenuation induced mostly LT muscle splitting (arrows) while (G) SERCA RNAi knockdown lead to affected myofiber growth with thin LT muscle phenotype (arrowheads). (H) Statistical representation of LT muscle phenotypes in *dRyR* mutants and LT targeted *dRyR* knockdown, gain-of-function and Cam and SERCA attenuation contexts. The statistical analyses were performed using Prism - contingency test; 50-60 segments/genotype. Scale bar: 10 µm.

Interestingly, live imaging (Fig. S4) shows that the sphere-shaped muscle phenotype arises from the impaired LT myotube extension and not from retraction of already extended myotubes. Also myonuclei remained on LT extremities and did not spread along the abnormally thin myofibers. The reduced number of myonuclei (2-4 per dRyR RNAi LT myofiber (Fig. S4B, lower panel) instead of 4-6 in control LTs (Fig. S4A lower panel)) points to the role of *dRyR* in the second wave of fusion (Eigler et al., 2021). This observation is consistent with the fact that overexpression of *dRyR* induced the LT split phenotype (Fig. 4E) known to be promoted by an excessive myoblast fusion (Bertin et al., 2021). Because the embryonic LT muscle defects in *dRyR*-mutant embryos are associated with a reduced calcium signal in LTs (Fig. S4 C, D), we hypothesize that *dRyR* acts as a promyogenic factor ensuring correct calcium levels in the developing myotubes.

Assessing the impact of the *RYR1* undiagnosed variant mutation in *Drosophila*

Drosophila dRyR shares 45% aa sequence identity with human RYR1 and RYR2, and all protein domains are conserved, with up to 75% of identity for the most C-terminal RIH domain (Fig. S5A). Thus, although the 3D conformation of the *Drosophila* dRyR has not yet been established, high sequence and positional conservation of functional domains suggest that the conformation of dRyR protein is similar to that of its vertebrate counterparts. Also, the distribution of pathogenic mutations identified in human *RYR1* and *RYR2* genes (reviewed by Lanner et al., 2010), clustered in three hot spots, correlates with the positions of conserved domains. As revealed by the identity heat map (Fig. S5B) the hot spot regions of human *RYR1 and RYR2* mutations align with the most conserved portions of the *Drosophila* dRyR indicating suitability of the *Drosophila dRyR* for modeling human *RYR* gene mutations and their impact on muscular and cardiac systems.

Over the last decades, whole genome sequencing has identified large numbers of variant mutations within the *RYR* genes, most of which are classified as variants of unknown significance (VUS). The recessive *c.14643G>A* / p.Met4881Ile missense *RYR1* mutation was identified in a young patient with a phenotype of congenital myopathy with a delayed acquisition of motor function. At the histopathological level, filamentous aggregates were present in muscle biopsies. This very rare mutation for which a link with a muscle disorder has not yet been evaluated, is located in the *RYR1* region encoding calcium pore.

We made use of the conserved muscle function and structural similarity between dRyR and human RYRs (Fig. S5A) demonstrated here to generate a *Drosophila* model of variant *p.Met4881Ile RYR1* and assess its impact on larval muscle function and structure (Fig. 6). The *p.Met4881Ile RYR1*

VUS-carrying larvae were homozygous-viable but were significantly smaller (Fig. 6B,I) than control larvae (Fig. 6A,I). They had shorter ventral longitudinal muscles (Fig. 6 D,J), which harbored fewer myonuclei (Fig. 6D,K) and were characterized by shorter sarcomeres (Fig. 6F,H) compared to control (Fig. 6C,E,G). As revealed by the larva motility tests (Fig. 6M, O) the *p.Met4881Ile RYR1* VUS impacted not only structural but also contractile muscle properties, leading to a reduced frequency of peristaltic body wall muscle contraction (Fig. 6N), slower larva locomotion (Fig. 60) and compromised muscle performance revealed by the righting test (Fig. 6M).

These structural and functional muscle phenotypes are reminiscent of those observed in *dRyR RNAi* larvae, suggesting that *p.Met4881Ile* variant mutation negatively influences *dRyR* expression and/or function and could likely contribute to RYR-related myopathies in humans.

Discussion

The ryanodine receptors encoding calcium release channels are key regulators of intracellular calcium level, largely conserved among vertebrate and invertebrate species. By their involvement in many calcium-dependent biological processes, RYR genes are vital for normal cellular functions, while mutations in RYR genes underlie a broad spectrum of human diseases including neuromuscular and cardiac disorders (Marks, 2023). Because of their large size (over 500 kDa),



Figure S4. Live imaging of developing LT muscles and GCAMP-revealed calcium levels in control and dRyR loss-of-function contexts.

Time-lapse images of developing LT muscles revealed by LifeActin-GFP (green) and myonuclei revealed by DsRed NLS (red) in (A) control Lms>LA; DsRed NLS; LacZ and (B) Lms>LA; DsRed NLS; dRyR RNAi embryos. (B) Arrows point to a growth-defective LT3 muscle and asterisks show the area where it is missing within the segment. Note a reduced myonuclei signal in dRyR RNAi context compared to control (red staining) indicating fewer myonuclei in LTs after *dRyR* attenuation. (C-D) Representative lateral views of LT muscles from late-stage 15 embryos stained with anti-GFP antibody to reveal cytoplasmic calcium detectable on GCaMP reporter binding. Calcium-dependent GCaMP signal was at a high level in control LTs (C) and comparatively weaker in $dRyR^{16}$ mutant LTs (D). Scale bar 10 µm.



Figure S5. **Schematic comparison of amino acid sequence of human RYR and Drosophila dRyR proteins.**

(A) Schematic representation of alignment of human RYR2 and *Drosophila* dRyR proteins with focus on Ins, MIR, RIH, SPRY, RYR, EF-hand and ITD protein domains. Percentage of identity for each domain is indicated on the dRyR protein scheme. (B) Schematic representation of pathogenic mutations in human *RYR1* and *RYR2*. Black vertical lines denote positions of mutations clustered into three hot spots. For the color code, see identity heat map. Position of variant mutation of unknown significance (VUS) (p.M4881I) is indicated with respect to distribution of pathogenic *RYR* mutations and *dRyR* conservation heat map. Below an extraction from the dRyR and RYR1 sequence alignment encompassing the VUS mutation. Mutated amino acid is in blue.



Figure 6. Modeling human RYR1 variant mutation in Drosophila.

(A,B) Age-matched 3rd instar wild-type (A) and *RyR1 p.Met4881Ile* mutant (B) larvae. Note a reduced size of larvae carrying *RYR1* variant mutation. (C,D) Representative views of ventral longitudinal (VL) muscles in wild type (C) and *RYR1* variant mutant larvae (D). Note slightly reduced VL3 muscle length and reduced number of myonuclei in mutant condition. (E-H) Z band profile revealing reduction of sarcomere length in *RYR1* variant context (F,H)) compared to control (E,G). Kettin is in green, Phalloidin in red and DAPI in blue. (I-L) Statistical representation of larva length (I) and structural muscle variables (J-L) in wild-type and *p.Met4881Ile RYR1* variant mutation contexts. (M-O) Statistical assessment of functional larval muscle performance using righting test (M), motility test (N) and locomotor test (O) in wild-type and *RYR1* mutant conditions. Scale bar: 1 mm in A-B; 50 mm in C-D; 20 mm in E-F. All statistical analyses were performed using Prism. The *t* test was used to compare control to variant context. Bar plot represent the mean and the standard deviation. On the figures, statistical comparisons of sample vs control are indicated as ****: P ≤ 0.0001; *: P ≤ 0.05.

structural complexity, many isoforms and broad spectrum of interacting factors, even though their role in promoting muscle contraction via E-C coupling is well-characterized, other RYR functions remain only partially understood. Here, we focus on *dRyR*, a single *Drosophila* member of the RYR gene family and characterize its expression and function in differentiated and developing muscle.

Drosophila dRyR shares 45% aa sequence identity with its human counterparts. Considering previous evolutionary distance studies (Ding et al., 2017) we show that the phylogenetic dRyR branch is connected to *RYR2*, the most ancient of the three human *RYRs*. Further, aa sequence alignment reveals an extensive conservation of all protein domains between *dRyR* and human RYRs, while a heatmap of conserved regions highlights previously identified hot spots of pathogenic *RYR1* and *RYR2* mutations. Remarkably, several aa residues at the functionally relevant channel pore domain (Wang et al., 2012) are conserved between *Drosophila* and humans.

Consistent with potential conservation of *dRyR* function in triggering Ca^{2+} dynamics across ER membranes, we detected ER-associated punctate dRyR protein expression in differentiated body wall muscles. Our data extend previously reported analyses (Sullivan et al., 2000; Vázquez-Martínez et al., 2003) providing evidence that *dRyR* is not only expressed in visceral muscle and the nervous system but also prominently in differentiated striated somatic and cardiac muscle. We also wanted to know whether different *dRyR* transcript isoforms were differentially expressed in body wall muscles. However, we did not detect any such differential expression with 4 HCR-FISH probes targeting alternative *dRyR* exons. The fact that most *dRyR* transcript isoforms are present in differentiated larval muscles is consistent with their common transcription start sites. However, whether all *dRyR* isoforms are collectively required for larval muscle function requires further investigation. In line with muscle-associated *dRyR* expression and the excitation-contraction coupling role of its vertebrate orthologs, RNAi knockdown of *dRyR* leads to reduced muscle contractility and severely impaired larva mobility. Interestingly, in addition to impaired muscle function, *dRyR* attenuation causes extensive structural muscle defects including reduced muscle size, smaller and aberrant sarcomeres and degraded mitochondria pattern. All these functional and structural muscle defects are reminiscent of those of aged muscle, indicating that maintenance of *dRyR*-triggered calcium management could prevent muscle aging. This applies also to cardiac muscle, which in the *dRyR RNAi* context shows aging-associated slow heart rate and arrhythmia (Blice-Baum et al., 2019).

dRyR transcripts and dRyR protein were also detected in the embryonic muscle precursors from embryonic stage 12 to late-stage embryos, indicating that *dRyR* could be involved in managing Ca^{2+} levels throughout myogenesis. In contrast to differentiated larval muscles, HCR-FISH experiments show that only a subset of *dRyR* splice isoforms is expressed in the developing muscles. Our developmental *dRyR* expression data, focusing on somatic muscle, extend previous more general analyses of *dRyR* expression and function (Takeshima et al., 1994; Sullivan et al., 2000; Vázquez-Martínez et al., 2003). Consistent with spatiotemporal embryonic *dRyR* expression and the role of cytoplasmic calcium management (Li et al., 2025), we show that *dRyR* loss of function and RNAi knockdown in developing muscles cause severe developmental muscle defects. We found that *dRyR* promoted myogenic differentiation and was required for myotube growth associated with myoblast fusion and followed by myonuclear spreading within the myotubes. Our observations in *Drosophila* are consistent with the promoting role of *RYR1* in the calcium-dependent myoblast-to-myotube fusion process reported by the Avinoam lab in an *in vitro* myogenic differentiation system (Eigler et al., 2021). Interestingly, our analyses of embryonic muscle phenotypes of hypomorph $dRyR^{16}$ embryo reveal that *dRyR*, in addition to its major promyogenic role, may also negatively influence myogenic differentiation. A negative influence on myogenic differentiation and in particular on myoblast fusion has recently been reported in mouse *RYR1* mutant myoblast culture (Tourel et al., 2025). It was suggested that this early developmental role of *RYR1* was calcium-independent. *dRyR* might thus play a dual role in myogenesis: (i) as a calcium-independent negative regulator of first myoblast-to-myoblast fusion events and (ii) as a positive regulator of myogenic differentiation acting in later steps of

myogenesis in a calcium-dependent way to promote myoblast-to-myotube fusion and muscle fiber growth. This major pro-myogenic *dRyR* function is further supported by the *dRyR* gain-of-function phenotypes.

The knowledge gained on *dRyR* and its muscle-associated functions prompted us to use *Drosophila* to test the impact of one human *RYR1* mutation with unknown significance. We chose undiagnosed recessive *p.Met4881Ile* variant mutation identified in a patient with congenital myopathy phenotypes, severely impaired mobility and accumulation of filamentous aggregates in muscle fibers. We found that *Drosophila* larvae carrying *p.Met4881Ile* mutation in the *dRyR* gene showed *dRyR RNAi*-like phenotypes with impaired larval mobility and significantly impaired sarcomeric muscle structure. In all, we assessed eight different functional and structural muscle variables showing that *p.Met4881Ile* variant mutation consistently impaired larval muscle performance and changed muscle size and structure. This suggests that the *p.Met4881Ile* mutation impairs *dRyR* function and is likely pathogenic.

To conclude, we report functional analysis of *dRyR*, the sole fruit fly *RyR* gene and show that in addition to ensuring contractile properties of differentiated striated muscle it plays a key pro-myogenic role during muscle development. Our findings advocate *Drosophila* for modeling and testing the impact of human *RYR1* variant mutations of unknown significance.

Materials & Methods

Drosophila strains and genetics

Fly stocks were maintained at 25°C on standard fly food.

The targeted expression experiments were performed using the UAS-GAL4 system (Brand and Perrimon, 1993) on the following GAL4 and UAS lines: C57-GAL4 (Bl32556); Hand-GAL4 (kindly provided by L. Perrin; TAGC, Aix-Marseille University, France); UAS-dRyR RNAi (BL29445); Lms-GAL4 (BL46861); UAS-mCherry RNAi (BL35785); UAS-dRyR (kindly provided by H. Nash University of Maryland College Park, Rockville, USA), UAS-lifeAct-GFP (BL35544), UAS-dsRed NLS (BL8547; BL8546), UAS-LacZ (BL1776), UAS-Cam RNAi (Bl34609), UAS-SERCA RNAi (BL44581) and UAS-GCaMP3 (BL32236). The RyR^{16}/CyO Wg LacZ (BL6812) was used as hypomorphic mutant and the w^{1118} strain was used as wild type.

Phylogenetic analysis

Initial trees for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the maximum composite likelihood (MCL) approach and then selecting the topology with superior log likelihood value (Kumar et al., 2018). The tree is drawn to scale, with branch lengths measured in number of substitutions per site. This analysis involved seven nucleotide sequences. Codon positions included were 1st+2nd+3rd+Noncoding. There were 17,322 positions in the final dataset.

Immunohistochemistry

Antibody staining was performed using standard protocol. Embryos were fixed in 4% formaldehyde and blocked in NGS serum to remove non–specific epitopes. They were incubated overnight at 4°C with primary antibodies followed by secondary antibodies for 2 h at RT.

$3^{rd.}$ instar larvae were dissected and fixed in 4% paraformaldehyde for 20 minutes as previously described (Lavergne et al., 2020). The fly hearts were dissected (Fink et al., 2009; Ocorr et al., 2007) and fixed for 15 min in 4% formaldehyde and the immunostaining procedure was performed as described (Auxerre-Plantié et al., 2019).

The following primary antibodies were used in this study: guinea pig anti-dRYR antibody (1:200, kindly provided by Robert Scott and Benjamin White from NIH/NIMH Institute and previously described in Gao et al., 2013), mouse anti-Dlg (1-50, DSHB, 4F3), rat anti-actin (1-500, Abcam, ab 50591), mouse anti-kettin (1:50 DSHB 1B8-3D9), mouse anti-ATP5A (1:200 Abcam, ab 14748), goat anti-GFP (1:500, Abcam, ab 5450), and chicken anti-β galactosidase (1:1000, Abcam, ab 9361).

Rhodamine phalloidin (ThermoFischer Scientific) was used to reveal actin filaments in the heart and muscles. Fluorescent secondary antibodies (Jackson ImmunoResearch) were used to detect primary antibodies.

Muscle characteristics measurements

All analyses of muscle length and sarcomere size were performed on fixed larval muscle preparations in a relaxed state. Acquired confocal images were analysed in Fiji using the *line tool*. *Analyze – Measure* tool was then applied to obtain muscle length values and measurements were analysed with Prism. Sarcomere size and number were calculated using *Analyze – Plot profile* Fiji tool. The sarcomere size was measured between peaks corresponding to Z-disc (revealed with Z-line specific marker) on approximatively 100 µm of muscle length. Sarcomere measurements were then analysed with Prism. DAPI-stained nuclei were counted in Z-stacks of confocal views of VL3 larval muscle and data analysed with Prism. About 30 larval muscles from 6-8 larval filets were analysed for each measurement.

In situ hybridization chain reaction – HCR

In this study we used the two-stage *in situ* HCR protocol described by Choi et al. (2016). This technique detects and amplifies specific transcripts by the direct binding of probes to nucleic target sequences without additional long-lasting enzymatic reaction. We planned four different mRNA probes targeting alternative exons numbered 10,11,22 and 23.

We used a Molecular Instruments HCR kit containing a DNA probe set, a DNA HCR amplifier B1-Alexa fluor 488, B2-fluor 532 and hybridization, wash and amplification buffers.

Fixed samples were pre-hybridized at 65°C for 2 h followed by hybridization steps overnight at 45°C. After several washes, the amplification step was performed overnight at RT in the dark. We used TRJ244 HCR amplifier B1, RTJ245 HCR amplifier B2, RTJ256 HCR amplifier B2, RTJ 247 HCR amplifier B1. Target mRNA sequence information remains at the discretion of Molecular Instruments Company. Excess of hairpins was removed by several washes with 5XSSCT solution at room temperature.

Imaging

Samples were mounted in Vectashield with DAPI (Vector Laboratories, Inc. Burlingame, CA) and a Leica SP8 confocal microscope was used for image acquisition and for time-lapse imaging of living embryos. *In vivo* imaging of lateral muscle was performed from late stage 14 to stage 16 every 3 min. We used Adobe Photoshop and ImageJ for image processing.

Genome editing

To generate the *Drosophila* model of human *RYR1* VUS p.Met4881Ile we applied the CRISPR-Cas9 homologous recombination genome editing approach with the use of single strand oligo donor (ssODN) and gRNA. A 20nt 5’-AAACGCTTCGTGTTCCATCTGTAC-3’ gRNA targeting the *dRYR* region close to the mutation site was designed using the OPTIMAL Target Finder platform (Gratz et al., 2014) and cloned into PCFD5 plasmid (Adgene). Single strand ssODN donor of 115 nt in size with sequence modification TTG to ATC was generated by IDT Company. Both components were injected at a concentration of 100 ng/µl by Best Gene into nos-Cas 9 (III-attp2) flies. PCR molecular screening with a pair of primers: Forward 5’-TGCAGAGCAGCCGGAGGATGAC; Reverse 5’-ATCAGAC GCGGCGAATCCGCAG and Sanger sequencing were used to identify progenies carrying the edited sequence. Genetic crosses established homozygous *Drosophila* lines carrying the RyR1 p.Met4881Ile variant mutation.

Functional tests of muscle performance

Motility tests were carried out on 30 3rd instar larvae as previously described (Picchio et al., 2013). The motility test was performed by recording the number of peristaltic contractions executed by the larva in 1 min on a grape medium plate. The righting test consisted in placing the

larva on its back and measuring the time it took to revert to its crawling position. For the locomotor test, a track 2 mm wide, 5 mm deep and 5 cm long was prepared on a grape medium plate. Larvae were placed on the test track and the time they took to crawl a distance of 5 cm was recorded.

Heartbeat analyses

The cardiac activity analyses of adult Drosophila hearts were performed on 1-week-old females flies using the Semi-automated Optical Heartbeat Analysis (SOHA) approach protocol of Fink et al. (2009). For each experiment about 20 flies were analyzed. The flies were anesthetized with Fly Nap, dissected in an oxygenated, artificial hemolymph composed of 108 mM NaCl, 5 mM KCl, 2 mM CaCl2, 8 mM MgCl2, 1 mM NaH2 PO4, 4 mM NaHCO3, 10 mM sucrose, 5 mM trehalose, 5 mM HEPES (pH 7.1). The beating hearts were filmed by digital camera on 30s movie with the speed of 150 frames/s (Digital camera C9300, Hamamatsu, McBain Instruments, Chatsworth, CA). The SOHA program based on Matlab R2009b software was used for film analysis (Fink et al., 2009).

Mitochondria area quantifications

The total area of mitochondria was identified by Otsu thresholding on Fiji for internal muscle z-planes. The quantifications for z-planes were averaged for each of 25-30 different VL3 muscle according to Zhang et al., (2024).

Statistic

All statistical analyses were performed using Prism (v9.5.1, GraphPad, Software, La Jolla, CA, USA). The *t* test was used to compare control to variant context and one-way ANOVA tests were used for comparisons with more than two datasets. Bar plot represent the mean and the standard deviation. On the figures, statistical comparisons of sample vs control are indicated as ****: P ≤ 0.0001; ***: P ≤ 0.001; **: P ≤ 0.01; *: P ≤ 0.05; ns > 0.05.

Ethical approval

This study was conducted in accordance with the ethical standards of the institutional and national research committees. Ethical approval was obtained from the appropriate institutional ethics committee under the reference 38RC21.0399

Data availability

All behavioral, phenotypical and image analyses datasets that were used to generate graphs in Figures 1, 2, S2, 3, 5 and 6 are available and will be provided as source.

Acknowledgements

We thank Drosophila Bloomington Stock Centers for Drosophila lines and L. Mouty for the technical assistance. This study was supported by the « Priority Research Programme on Rare Diseases » of the French Investments for the Future Programme, by the AFM-Telethon strategic grant to MyoNeurAlp consortium, the Reference Centre for Neuromuscular Diseases grant to MZ and CS, ANR-iSITE-2025 grant to MZ, by the French Government Scholarship grant to MMP and The Polish National Agency for Academic Exchange within The Bekker Programme (grant no. BPN/BEK/2021/2/00006) to MDM.

Additional information

Funding

Funder	Grant reference number	Author
Institut National de la Santé et de la Recherche Médicale (Inserm)	RYR-ClassifAI	John Rendu Krzysztof Jagla

Department of Agriculture, Food and the Marine, Ireland (DAFM)	MyoNeuralp	Monika Zmojdzian
Agence Nationale de la Recherche (ANR)	iSITE CAP2025	Krzysztof Jagla Catherine Sarret
Bekker Programme	BPN/BEK/2021/2/00006	Magda Dubinska-Magiera Marta Migocka-Patrzałek

Author ORCID iDs

Monika Zmojdzian: https://orcid.org/0000-0001-6174-2719
John Rendu: https://orcid.org/0000-0002-0377-0807
Krzysztof Jagla: https://orcid.org/0000-0003-4965-8818

References

1. **Auxerre-Plantié E,** Nakamori M, Renaud Y, Huguet A, Choquet C, Dondi C, Miquerol L, Takahashi MP, Gourdon G, Junion G, *et al.* (2019) Straightjacket/α2δ3 deregulation is associated with cardiac conduction defects in myotonic dystrophy type 1. *eLife* **8**:e51114 https://doi.org/10.7554/eLife.51114 | PubMed
2. **Bertin B,** Renaud Y, Jagla T, Lavergne G, Dondi C, Da Ponte JP, Junion G, Jagla K. (2021) Gelsolin and dCryAB act downstream of muscle identity genes and contribute to preventing muscle splitting and branching in Drosophila. *Sci Rep* **11**:13197 https://doi.org/10.1038/s41598-021-92506-3 | PubMed
3. **Blice-Baum AC,** Guida MC, Hartley PS, Adams PD, Bodmer R, Cammarato A. (2019) As time flies by: Investigating cardiac aging in the short-lived Drosophila model. *Biochim Biophys Acta Mol Basis Dis* **1865**:1831-1844 https://doi.org/10.1016/j.bbadis.2018.11.010 | PubMed
4. **Brand AH,** Perrimon N. (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**:401-415 https://doi.org/10.1242/dev.118.2.401 | PubMed
5. **Choi HM,** Calvert CR, Husain N, Huss D, Barsi JC, Deverman BE, Hunter RC, Kato M, Lee SM, Abelin AC, *et al.* (2016) Mapping a multiplexed zoo of mRNA expression. *Development* **143**:3632-3637 https://doi.org/10.1242/dev.140137 | PubMed
6. **De Mandal S,** Shakeel M, Prabhakaran VS, Karthi S, Xu X, Jin F. (2019) Alternative splicing and insect ryanodine receptor. *Archives of Insect Biochemistry and Physiology* **102**:e21590 https://doi.org/10.1002/arch.21590 | PubMed
7. **Ding Z,** Peng J, Liang Y, Yang C, Jiang G, Ren J, Zou Y. (2017) Evolution of Vertebrate Ryanodine Receptors Family in Relation to Functional Divergence and Conservation. *International Heart Journal* **58**:969-977 https://doi.org/10.1536/ihj.16-558 | PubMed
8. **Eigler T,** Zarfati G, Amzallag E, Sinha S, Segev N, Zabary Y, Zaritsky A, Shakked A Umansky KB, Schejter ED, Millay DP, *et al.* (2021) ERK1/2 inhibition promotes robust myotube growth via CaMKII activation resulting in myoblast-to-myotube fusion. *Dev Cell* **56**:3349-3363. https://doi.org/10.1016/j.devcel.2021.11.022 | PubMed
9. **Fill M,** Copello JA (2002) Ryanodine Receptor Calcium Release Channels. *Physiological Reviews* **82**:893-922 https://doi.org/10.1152/physrev.00013.2002 | PubMed
10. **Fink M,** Callol-Massot C, Chu A, Ruiz-Lozano P, Izpisua Belmonte JC, Giles W, Bodmer R, Ocorr K. (2009) A new method for detection and quantification of heartbeat parameters in Drosophila, zebrafish, and embryonic mouse hearts. *Biotechniques* **46**:101-13 https://doi.org/10.2144/000113078 | PubMed
11. **Fruen BR,** Black DJ, Bloomquist RA, Bardy JM, Johnson JD, Louis CF, Balog EM (2003) Regulation of the RYR1 and RYR2 Ca2+ release channel isoforms by Ca2+-insensitive mutants of calmodulin. *Biochemistry* **42**:2740-7 https://doi.org/10.1021/bi0267689 | PubMed

12. **George CH,** Rogers SA, Bertrand BMA, Tunwell REA, Thomas NL, Steele DS, Cox EV, Pepper C, Hazeel CJ, Claycomb WC, *et al.* (2007) Alternative Splicing of Ryanodine Receptors Modulates Cardiomyocyte Ca 2+ Signaling and Susceptibility to Apoptosis. *Circulation Research* **100**:874-883 https://doi.org/10.1161/01.res.0000260804.77807.cf | PubMed

13. **Gao S,** Sandstrom DJ, Smith HE, High B, Marsh JW, Nash HA (2013) Drosophila ryanodine receptors mediate general anesthesia by halothane. *Anesthesiology* **118**:587-601 https://doi.org/10.1097/aln.0b013e31827e52c6 | PubMed

14. **Gratz SJ,** Ukken FP, Rubinstein CD, Thiede G, Donohue LK, Cummings AM, O'Connor-Giles KM. (2014) Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila. *Genetics* **196**:961-71 https://doi.org/10.1534/genetics.113.160713 | PubMed

15. **Hadiatullah H,** He Z, Yuchi Z. (2022) Structural Insight Into Ryanodine Receptor Channelopathies. *Front Pharmacol* **13**:897494 https://doi.org/10.3389/fphar.2022.897494 | PubMed

16. **Hasan G,** Rosbash M. (1992) Drosophila homologs of two mammalian intracellular Ca2+-release channels: Identification and expression patterns of the inositol 1,4,5-triphosphate and the ryanodine receptor genes. *Development* **116**:967-975 https://doi.org/10.1242/dev.116.4.967 | PubMed

17. **Howe K,** Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, Collins JE, Humphray S, McLaren K, Matthews L, *et al.* (2013) The zebrafish reference genome sequence and its relationship to the human genome. *Nature* **496**:498-503 https://doi.org/10.1038/nature12111 | PubMed

18. **Jenden DJ,** Fairhurst AS (1969) The pharmacology of ryanodine. *Pharmacol Rev* **21**:1-25 https://doi.org/10.1016/s0031-6997(25)06870-x | PubMed

19. **Kimura M.** (1980) A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. *Journal of Molecular Evolution* **16**:111-120 https://doi.org/10.1007/bf01731581 | PubMed

20. **Klatt Shaw D,** Gunther D, Jurynec MJ, Chagovetz AA, Ritchie E, Grunwald DJ (2018) Intracellular Calcium Mobilization Is Required for Sonic Hedgehog Signaling. *Developmental Cell* **45**:512-525.e5 https://doi.org/10.1016/j.devcel.2018.04.013 | PubMed

21. **Kumar S,** Stecher G, Li M, Knyaz C, Tamura K. (2018) MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. *Molecular Biology and Evolution* **35**:1547-1549 https://doi.org/10.1093/molbev/msy096 | PubMed

22. **Lanner JT,** Georgiou DK, Joshi AD, Hamilton SL (2010) Ryanodine Receptors: Structure, Expression, Molecular Details, and Function in Calcium Release. *Cold Spring Harbor Perspectives in Biology* **2**:a003996-a003996 https://doi.org/10.1101/cshperspect.a003996 | PubMed

23. **Lanner JT** (2012) Ryanodine receptor physiology and its role in disease. *Adv Exp Med Biol* **740**:217-234 https://doi.org/10.1007/978-94-007-2888-2_9 | PubMed

24. **Lavergne G,** Zmojdzian M, Da Ponte JP, Junion G, Jagla K. (2020) Drosophila adult muscle precursor cells contribute to motor axon pathfinding and proper innervation of embryonic muscles. *Development* **147** https://doi.org/10.1242/dev.183004 | PubMed

25. **Li X,** Zhao X, Qin Z, Li J, Sun B, Liu L. (2025) Regulation of calcium homeostasis in endoplasmic reticulum-mitochondria crosstalk: implications for skeletal muscle atrophy. *Cell Commun Signal* **23**:17 https://doi.org/10.1186/s12964-024-02014-w | PubMed

26. **Liu Q,** Chen B, Yankova M, Morest DK, Maryon E, Hand AR, Nonet ML, Wang ZW (2005) Presynaptic Ryanodine Receptors Are Required for Normal Quantal Size at the Caenorhabditis elegans Neuromuscular Junction. *The Journal of Neuroscience* **25**:6745-6754 https://doi.org/10.1523/jneurosci.1730-05.2005 | PubMed

27. **Mackrill JJ** (2012) Ryanodine Receptor Calcium Release Channels: An Evolutionary Perspective. In: Islam Md. S. (Ed). *Calcium Signaling* **740** Springer Netherlands. pp. 159-182 https://doi.org/10.1007/978-94-007-2888-2_7 | PubMed

28. **Marks AR** (2023) Targeting ryanodine receptors to treat human diseases. *J Clin Invest* **133**:e162891 https://doi.org/10.1172/jci162891 | PubMed

29. **Maryon EB,** Coronado R, Anderson P. (1996) Unc-68 encodes a ryanodine receptor involved in regulating C. elegans body-wall muscle contraction. *The Journal of Cell Biology* **134**:885-893 https://doi.org/10.1083/jcb.134.4.885 | PubMed

30. **McKay PB,** Griswold CK (2014) A comparative study indicates both positive and purifying selection within ryanodine receptor (RyR) genes, as well as correlated evolution: DIVERGENCE AND CORRELATED EVOLUTION OF RyRs. *Journal of Experimental Zoology Part A: Ecological Genetics and Physiology* **321**:151-163 https://doi.org/10.1002/jez.1845 | PubMed

31. **Murayama T,** Kurebayashi N. (2011) Two ryanodine receptor isoforms in nonmammalian vertebrate skeletal muscle: Possible roles in excitation–contraction coupling and other processes. *Progress in Biophysics and Molecular Biology* **105**:134-144 https://doi.org/10.1016/j.pbiomolbio.2010.10.003 | PubMed

32. **Nishimura M,** Ocorr K, Bodmer R, Cartry J. (2011) Drosophila as a model to study cardiac aging. *Exp Gerontol* 326-30 https://doi.org/10.1016/j.exger.2010.11.035 | PubMed

33. **Ocorr K,** Reeves NL, Wessells RJ, Fink M, Chen HS, Akasaka T, Yasuda S, Metzger JM, Giles W, Posakony JW, *et al.* (2007) KCNQ potassium channel mutations cause cardiac arrhythmias in Drosophila that mimic the effects of aging. *Proc Natl Acad Sci U S A* **04**:3943-8 https://doi.org/10.1073/pnas.0609278104 | PubMed

34. **Ottini L,** Marziali G, Conti A, Charlesworth A, Sorrentino V. (1996) α and β isoforms of ryanodine receptor from chicken skeletal muscle are the homologues of mammalian RyR1 and RyR3. *Biochemical Journal* **315**:207-216 https://doi.org/10.1042/bj3150207 | PubMed

35. **Picchio L,** Plantie E, Renaud Y, Poovthumkadavil P., Jagla K. (2013) Novel Drosophila model of myotonic dystrophy type 1: phenotypic characterization and genome-wide view of altered gene expression. *Hum. Mol. Genet* **22**:2795-2810 https://doi.org/10.1093/hmg/ddt127 | PubMed

36. **Postlethwait JH,** Yan YL, Gates MA, Horne S, Amores A, Brownlie A, Donovan A, Egan ES, Force A., Gong Z., *et al.* (1998) Vertebrate genome evolution and the zebrafish gene map. *Nature Genetics* **18**:345-349 https://doi.org/10.1038/ng0498-345 | PubMed

37. **Quinn KE,** Castellani L, Ondrias K, Ehrlich BE (1998) Characterization of the ryanodine receptor/channel of invertebrate muscle. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology* **274**:R494-R502 https://doi.org/10.1152/ajpregu.1998.274.2.r494 | PubMed

38. **Sinha S,** Elbaz-Alon Y, Avinoam O. (2022) Ca2+ as a coordinator of skeletal muscle differentiation, fusion and contraction. *Febs J* **289**:6531-6542 https://doi.org/10.1111/febs.16552 | PubMed

39. **Stecher G,** Tamura K, Kumar S. (2020) Molecular Evolutionary Genetics Analysis (MEGA) for macOS. *Molecular Biology and Evolution* **37**:1237-1239 https://doi.org/10.1093/molbev/msz312 | PubMed

40. **Suisse A,** Treissman JE (2019) Reduced SERCA Function Preferentially Affects Wnt Signaling by Retaining E-Cadherin in the Endoplasmic Reticulum. *Cell Rep* **26**:322-329. https://doi.org/10.1016/j.celrep.2018.12.049 | PubMed

41. **Sullivan KMC,** Scott K, Zuker CS, Rubin GM (2000) The ryanodine receptor is essential for larval development in Drosophila melanogaster. *Proceedings of the National Academy of Sciences* **97**:5942-5947 https://doi.org/10.1073/pnas.110145997 | PubMed

42. **Takeshima H,** Nishi M, Iwabe N, Miyata T, Hosoya T, Masai I, Hotta Y. (1994) Isolation and characterization of a gene for a ryanodine receptor/calcium release channel in Drosophila melanogaster. *FEBS Letters* **337**:81-87 https://doi.org/10.1016/0014-5793(94)80634-9 | PubMed

43. **Tourel A,** Reynaud-Dulaurier R, Brocard J, Fauré J, Marty I, Petiot A. (2025) RyR1 Is Involved in the Control of Myogenesis. *Cells* **14**:158 https://doi.org/10.3390/cells14030158 | PubMed

44. **Vázquez-Martínez O,** Cañedo-Merino R, Díaz-Muñoz M, Riesgo-Escovar JR (2003) Biochemical characterization, distribution and phylogenetic analysis of Drosophila melanogaster ryanodine and IP3 receptors, and thapsigargin-sensitive Ca2+ ATPase. *Journal of Cell Science* **116**:2483-2494 https://doi.org/10.1242/jcs.00455 | PubMed

45. **Wang J,** Li Y, Han Z, Zhu Y, Xie Z, Wang J, Liu Y., Li X. (2012) Molecular Characterization of a Ryanodine Receptor Gene in the rice Leaffolder, Cnaphalocrocis medinalis. *PLoS ONE* **7**:e36623 https://doi.org/10.1371/journal.pone.0036623 | PubMed

46. **Wu HH,** Brennan C, Ashworth R. (2011) Ryanodine receptors, a family of intracellular calcium ion channels, are expressed throughout early vertebrate development. *BMC Research Notes* **4**:541 https://doi.org/10.1186/1756-0500-4-541 | PubMed

47. **Zhang X,** Avellaneda J, Spletter ML, Lemke SB, Mangeol P, Habermann BH, Schnorrer F. (2024) Mechanoresponsive regulation of myogenesis by the force-sensing transcriptional regulator Tono. *Curr Biol* **34**:4143-4159.e6 https://doi.org/10.1016/j.cub.2024.07.079 | PubMed

48. **Xu X,** Bhat MB, Nishi M, Takeshima H., Ma J. (2000) Molecular cloning of cDNA encoding a Drosophila Ryanodine Receptor and functional studies of the Carboxyl-Terminal Calcium Release Channel. *Biophys. J* **78**:1270-1281 https://doi.org/10.1016/s0006-3495(00)76683-5 | PubMed

Peer reviews

Reviewer #1 (Public review):

Summary:

In this manuscript, Zmojdzian et al. provide an analysis of ryanodine receptor (RyR) expression and function in Drosophila. They also use CRISPR to engineer into flies a RyR variant of unknown significance (VUS) found in a human myopathy patient and demonstrate that it is likely a pathogenic mutation. From studies of RyR expression in embryonic and larval stages, and effects of RyR knockdown or overexpression in various muscle groups, the authors show that, in addition to its known actions in calcium-dependent excitation-contraction coupling, RyR promotes myogenesis during development.

The key conclusions of the paper are convincing. I do not have suggestions for necessary additional experimental work, and my comments are minor. One conclusion, that RyR dysfunction may be involved in aging, is stated in multiple places, sometimes speculatively but once very forcefully. The latter is in the final paragraph of the Discussion, which states RyR "plays an instrumental anti-aging role in differentiated striated muscle". This conclusion must be tempered, as even if RyR knockdown phenotypes resemble some of those seen in aging flies, the study does not examine aged flies, and there is no mechanistic analysis that might link the two. I assume the authors would prefer to modify that sentence than initiate work with aging flies to prove the assertion. Finally, the use of CRISPR to test a VUS is excellent and suggests a good way for testing of additional RyR variants in the future.

Significance:

The paper is significant in that RyR is known to be a critical protein in calcium-dependent excitation-contraction coupling but its role in developmental myogenesis is poorly studied. This study demonstrates that it is expressed during, and is important for, embryonic and larval myogenesis in the fly. RyR is also understudied in this valuable model organism, even though a P element-based mutant has been available since 2000. The mechanistic basis for the functional observations is not explored here but the work is well performed and will be of interest to investigators studying muscle development (my own field) and diseases caused by RyR mutations.

https://doi.org/10.7554/eLife.111053.1.sa2

Reviewer #2 (Public review):

Summary:

This paper presents data using the Drosophila model to analyze the effects of a rare human mutation in the gene encoding the ryanodine receptor (ryr). The authors present a nice, comprehensive phylogenetic analysis that shows the Drosophila version of Ryr to be most similar to human RYR2 and that the known "hot spots" for mutations in RYR2 coincide with highly conserved regions of the Drosophila Ryr. They characterize the functional effects of ryr knockdown and overexpression on both adult heart function and larval body wall muscle. They identified embryonic ryr expression in association with actin-stained muscle precursor cells and provide beautiful stains, which clearly showed that embryonic muscle cell development was disrupted in ryr mutants. In support of these findings, KD of Calmodulin in larva (an Ryr inhibitor) phenocopied Ryr OE. They recreated a human variant of unknown function (RyR1 p.Met4881Ile) in the conserved region of the fly gene and tested the effect on larval muscle. Their data suggested that this variant was likely deleterious as it negatively affected most muscle parameters.

Major comments:

(1) Fig, 1 In G there is no data for the RNAi KD situation.

(2) Fig. 2 Authors should include Diastolic Diameters; they mention dilated cardiomyopathy but don't show the dilation. The authors should also show staining in hearts with RYR OE and RNAi. It would be nice to have some kind of quantification of disorganized myofibrils.

(3) To evaluate and reproduce the data on the larva muscle parameters the authors should provide more details on how sarcomere length was quantified in each larva (replicates, ROI size, etc). Similarly, how were # of nuclei quantified / normalized? Importantly for these measurements, did the authors know what the contraction state of the muscles were when fixed?

(4) Fig. 3, Are RNAi and OE in the same background? I only see one control in the graphs for the RNAi line background.

(5) Fig. 3 How VL3 length was determined needs more detail, the Zhang ref is not adequate.

(6) In order to be able to evaluate the data, the statistical tests used should be cited in the figure legends along with what *, ** ,*** stand for (or just provide p values).

Significance:

The authors nicely characterized the role of Ryr in muscle development and function and recreated a human variant of unknown function (RyR1 p.Met4881Ile) in the conserved region of the fly gene. Their data suggested that this variant was likely deleterious as it negatively affected most muscle parameters. This work supports a role for the fly model in testing potential human disease gene variants.

Comments on Revised Version:

The authors have very adequately addressed the points raised by all reviewers.

https://doi.org/10.7554/eLife.111053.1.sa1

Author response:

> ***General Statements***

We would like to extend our gratitude to all reviewers for their supportive feedback, which acknowledges our study as well performed and of interest to investigators studying muscle development and diseases and supporting a role for the fly model in testing potential human disease gene variants. We also thank the reviewers for their valuable critical comments. We

carefully considered all of them and made additional experiments and suggested text amendments.

We believe these modifications substantially improve the quality of our results and enhance general interest of our work.

> ***Point-by-point description of the revisions***
>
> ***Reviewer #1:***
>
> *In this manuscript, Zmojdzian et al. provide an analysis of ryanodine receptor (RyR) expression and function in Drosophila. They also use CRISPR to engineer into flies a RyR variant of unknown significance (VUS) found in a human myopathy patient and demonstrate that it is likely a pathogenic mutation. From studies of RyR expression in embryonic and larval stages, and effects of RyR knockdown or overexpression in various muscle groups, the authors show that, in addition to its known actions in calcium-dependent excitation-contraction coupling, RyR promotes myogenesis during development.*
>
> *The key conclusions of the paper are convincing. I do not have suggestions for necessary additional experimental work, and my comments are minor. One conclusion, that RyR dysfunction may be involved in aging, is stated in multiple places, sometimes speculatively but once very forcefully. The latter is in the final paragraph of the Discussion, which states RyR "plays an instrumental anti-aging role in differentiated striated muscle". This conclusion must be tempered, as even if RyR knockdown phenotypes resemble some of those seen in aging flies, the study does not examine aged flies, and there is no mechanistic analysis that might link the two. I assume the authors would prefer to modify that sentence than initiate work with aging flies to prove the assertion.*

We thank the Reviewer for this comment and remove from the concluding sentence hypothetical anti-aging role of RyR. The modified sentence reads as follow:

“To conclude, we report functional analysis of dRyR, the sole fruit fly RyR gene and show that in addition to ensuring contractile properties of differentiated striated muscle it plays a key pro-myogenic role during muscle development.”

> *Finally, the use of CRISPR to test a VUS is excellent and suggests a good way for testing of additional RyR variants in the future.*
>
> *Minor comments:*
>
> *(1) Figure 1A: In the Introduction it is stated that non-mammalian vertebrates have two RyR genes, alpha and beta. In Fig. 1A, a single chicken and single frog gene are listed under names different than alpha or beta. The figure also focuses on RyR2 genes, yet the Introduction states that the non-mammalian vertebrate genes are homologous to RyR1 and RyR3 in mammals. The dichotomy between the text and the figure is confusing. Finally, the font used in Fig. 1A should be enlarged for better visibility.*

To avoid the dichotomy we modified our sentence concerning the non-mammalian vertebrate RYR genes in the Introduction section. As indicated, there are two RYR genes in chicken and frog, with one that shares homology with vertebrate RYR2 and is represented in the phylogenetic tree (Fig. 1A). As requested by the reviewer, to ensure better visibility we enlarged the font in the revised Fig. 1A.

> *(2) Figure 3G-I: IF to Kettin is used to reveal sarcomeres but is not mentioned in the text. This protein is not present in vertebrates (I believe) and may not be familiar to many readers. It should be described in the text when it is used.*

We are grateful for reminding us to provide information about Kettin, which represents the Drosophila counterpart of Titin. The following information has been added to the text on page 9: " …which in turn correlated with shortening of Kettin/D-Titin-labelled sarcomeres…"

> *(3) Figure S2: The panels are labelled E, F, G. They should be A-D, as is used in the text.*

In the revised version of Fig. S2 panel labels were amended and the panel E view enlarged. We also provide an additional control context (C57>LacZ).

> *(4) The dRyR16 allele is used in Figure 5 and S4. It is described as a hypomorph in the text on page 12 but as a null in the legend to Figure 5. Do the authors actually mean "homozygous" in the legend? The difference should be clarified.*

The $dRyR^{16}$ allele has been previously described as hypomorph. Indeed, in the legend of Fig. 5 we by mistake describe it as a "null". As suggested by the Reviewer we modify it to « homozygous ».

> *(5) The Met codon that is mutated in the variant studied in Figure S5 and Figure 6 is position 488 in humans. It is referred to that way in the fly version also. Is that true, the actual amino acid number is identical in humans and flies? In Figure S5B, it might be worth showing the primary amino acid sequence surrounding Met488 to reveal the degree of local conservation (beyond the orange domain in that panel).*

To provide more information about the conservation we include to the revised Fig. S5 an alignment of amino acid sequence surrounding the human RYR1 4881 variant position, which corresponds to position 4971 in the Drosophila dRyR.

Author response image 1 shows a snapshot from a larger portion of alignment encompassing variant mutation showing a high amino acids conservation around the variant position:

```
  Fly   4942 IYTVIAFNFFRKFYIQEEDE-EVDKKCHDMLTCFVFHLYKGVRAGGGIGDEIGDPDGDDYEVYRI 5005
             :|||:|||||||||.:.||| |.|.||.||:||::||:|.||||||||||||.||.||:||:||:
Human   4851 LYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRV 4915
```

Author response image 1.

> *(6) At least two references cited in the text are not listed in the References section (Hadiatullah et al. and Nishimura et al.).*

We double check reference citation and two indicated positions are now listed in the References section.

> ***Reviewer #1 (Significance):***
>
> *The paper is significant in that RyR is known to be a critical protein in calcium-dependent excitationcontraction coupling but its role in developmental myogenesis is poorly studied. This study demonstrates that it is expressed during, and is important for, embryonic and larval myogenesis in the fly. RyR is also understudied in this valuable model organism, even though a P element-based mutant has been available since 2000. The mechanistic basis for the functional observations is not explored here but the work is*

> *well performed and will be of interest to investigators studying muscle development (my own field) and diseases caused by RyR mutations.*

To reinforce mechanistic/functional side of our studies we include to the revised Fig.5 a new panel G showing promyogenic role of another major cellular calcium regulator, ER calcium pump SERCA. The Lms targeted RNAi knockdown of SERCA leads to affected myotube growth resulting in a thin muscle fiber phenotype. This indicates that both dRyR-regulated cytosolic and SERCA-regulated ER store calcium levels are required to promote muscle development.

> ***Reviewer #2:***
>
> *Summary:*
>
> *This paper presents data using the Drosophila model to analyze the effects of a rare human mutation in the gene encoding the ryanodine receptor (ryr). The authors present a nice, comprehensive phylogenetic analysis that shows the Drosophila version of Ryr to be most similar to human RYR2 and that the known "hot spots" for mutations in RYR2 coincide with highly conserved regions of the Drosophila Ryr. They characterize the functional effects of ryr knockdown and overexpression on both adult heart function and larval body wall muscle. They identified embryonic ryr expression in association with actin-stained muscle precursor cells and provide beautiful stains, which clearly showed that embryonic muscle cell development was disrupted in ryr mutants. In support of these findings, KD of Calmodulin in larva (an Ryr inhibitor) phenocopied Ryr OE. They recreated a human variant of unknown function (RyR1 p.Met4881Ile) in the conserved region of the fly gene and tested the effect on larval muscle. Their data suggested that this variant was likely deleterious as it negatively affected most muscle parameters. This work supports a role for the fly model in testing potential human disease gene variants.*
>
> *Major comments:*
>
> *(1) Fig, 1 In G there is no data for the RNAi KD situation.*

We are grateful to the Reviewer for pointing this out. We initially didn't include these data because of large difference in crawling capacities of dRyR RNAi larvae. In the revised version of Fig. 1 we provide now dRyR-RNAi larva crawling data. Because of their inefficient crawling, the time scale in panel 1G was modified.

> *(2) Fig. 2 Authors should include Diastolic Diameters; they mention dilated cardiomyopathy but don't show the dilation. The authors should also show staining in hearts with RYR OE and RNAi. It would be nice to have some kind of quantification of disorganized myofibrils.*

As requested, in the revised Fig. 2 we provide diastolic diameter measures. We also include systolic interval graph to show a full picture of cardiac parameters. We do not observe all signs of dilated cardiomyopathy in dRyR-RNAi context as there is systolic diameter increase but no significant change in diastolic diameter.

We modify our comments in the text accordingly (page 7).

"…As the diastolic diameter remained unchanged, we conclude that cardiac dRyR knockdown affects cardiac performance without causing dilated cardiomyopathy…"

Regarding circular myofibrils pattern, we do not observe irregularity of myofibrils orientation but rather a fuzzy and less distinctive sarcomeric pattern that is difficult to quantify. We specify this in the figure 2 legend (page 8).

"…circular fibers in Hand>dRyR RNAi (E) context showed a fuzzy pattern suggesting an affected sarcomeric organisation…"

Author response image 2 shows the entire view of the cardiac tube in dRyRRNAi context (stained with phalloidin) in which in spite of less distinctive circular myofibrils no obvious differences with wt are observed.

```
  Fly   4942 IYTVIAFNFFRKFYIQEEDE-EVDKKCHDMLTCFVFHLYKGVRAGGGIGDEIGDPDGDDYEVYRI 5005
             :|||:|||||||||.:.||| |.|.||.||:||::||:|.||||||||||||.||.||:||:||:
Human   4851 LYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRV 4915
```

Author response image 2.

> *(3) To evaluate and reproduce the data on the larva muscle parameters the authors should provide more details on how sarcomere length was quantified in each larva (replicates, ROI size, etc). Similarly, how were # of nuclei quantified / normalized? Importantly for these measurements, did the authors know what the contraction state of the muscles were when fixed?*

We add the requested information to the Materials and Methods section:

“Muscle characteristics measurements:

All analyses of muscle length and sarcomere size were performed on fixed larval muscle preparations in a relaxed state. Acquired confocal images were analysed in Fiji using the line tool. Analyze – Measure tool was then applied to obtain muscle length values and measurements were analysed with Prism. Sarcomere size and number were calculated using Analyze – Plot profile Fiji tool. The sarcomere size was measured between peaks corresponding to Z-disc (revealed with Z-line specific marker) on approximatively 100 µm of muscle length. Sarcomere measurements were then analysed with Prism.

DAPI-stained nuclei were counted in Z-stacks of confocal views of VL3 larval muscle and data analysed with Prism. About 30 larval muscles from 6-8 larval filets were analysed for each measurement. » Statistics

All statistical analyses were performed using Prism (v9.5.1, GraphPad, Software, La Jolla, CA, USA). The t test was used to compare control to variant context and one-way ANOVA tests were used for comparisons with more than two datasets. Bar plot represent the mean and the standard deviation. On the figures, statistical comparisons of sample vs control are indicated as ****: $P \leq 0.0001$; ***: $P \leq 0.001$; **: $P \leq 0.01$; *: $P \leq 0.05$; ns > 0.05.

> *(4) Fig. 3, Are RNAi and OE in the same background? I only see one control in the graphs for the RNAi line background.*

We agree and to avoid potential bias between the RNAi versus OE genetic contexts we provide now in the revised version of Fig. 3 an additional OE control (C57>lacZ).

Thus, two controls, one for RNAi and one for OE contexts are now included.

> *(5) Fig. 3 How VL3 length was determined needs more detail, the Zhang ref is not adequate.*

We are thanking the Reviewer for this comment and provide now more details about the method used to calculate VL3 length (new paragraph in Materials and Methods), see also our answer to point 3. Zhang et al. reference is in relation to the mitochondria pattern quantification.

> *(6) In order to be able to evaluate the data, the statistical tests used should be cited in the figure legends along with what *, ** ,*** stand for (or just provide p values).*

We add now the information about the statistical tests to the Fig legends in addition to the specific paragraph in Materials and Methods section (answer to point 3).

> *Minor comments:*
>
> *(1) Need more detail in the figures, e.g. add what colors go with which stain to the picture.*

We provide this information in the revised version of the figure legends

> *(2) Page 13, (Fig. ?F, G).*

We apologize for this mistake and add the number - Fig. 5

> *(3) Fig. 4 "partially co-localizing with actin".... this is confusing and probably an overstatement based on the staining pattern in a whole embryo and not on an optical section or a higher power image with a more restricted field of view.*

We agree and remove this statement from the Fig.4 legend.

> *(4) Some of the graphs are a bit small, recommend reducing the statistical comparison brackets to straight lines, which eliminates a lot of white space and would allow the graphs to be enlarged.*

We increased the size of graphs in revised Fig. S2 and Fig.5.

> ***Reviewer #2 (Significance):***
>
> *The authors nicely characterized the role of Ryr in muscle development and function and recreated a human variant of unknown function (RyR1 p.Met4881Ile) in the conserved region of the fly gene. Their data suggested that this variant was likely deleterious as it negatively affected most muscle parameters. This work supports a role for the fly model in testing potential human disease gene variants. The reviewers field of expertise is in Drosophila genetics and in the use of the fly as a model system for understanding the genetic networks contributing to muscle structure and function at the cellular level.*
>
> ***Reviewer #3:***
>
> *Summary*
>
> *This paper examines the Drosophila Ryanodine Receptor (RyR or dRyR). Ryanodine receptors are enormous channel proteins that mediate calcium efflux from the endoplasmic reticulum and sarcoplasmic reticulum. One goal of the work is to describe salient developmental features of Drosophila RyR (i.e., where it localizes in the cell and how it contributes to muscle development and function) and to refine knowledge from prior reports. Many of the analyses toward that goal are well done; this reviewer especially likes the examination of how muscles develop (Fig. 5).*
>
> *Another goal is to compare this information with what is known about mammalian RyRs. There seems to be a lot in common between Drosophila and mammalian RyRs. The paper finishes by taking a human ryanodine receptor variant of unknown significance and generating the corresponding amino-acid substitution in Drosophila RyR. The substitution has some phenotypic consequences for fly coordination, so the authors conclude that the human variant is likely to be pathogenic.*

> *In terms of investigation, a refined description of RyR biology is welcome. Ryanodine receptors are critical contributors/mediators of intracellular calcium signaling processes. Understanding their properties can help to contextualize the results of studies where calcium dynamics are at play. This is true of for both Drosophila and non-Drosophila work. For this version of the paper, there are several statements that should be edited, both in terms of accuracy and in terms of reporting prior knowledge. Additionally, some experiments are missing controls or reagent verification. Importantly, the anti-RyR antibody needs supporting information regarding its specificity.*
>
> *Main Comments*
>
> *(1) The paper does not fully state what has been done before in terms of studying Drosophila ryanodine receptor expression. In comparing the work on ryanodine receptors in vertebrates versus Drosophila, the authors write, "By contrast, no systematic analyses have yet been performed to assess the expression of the sole Drosophila dRyR gene." I was a little surprised by this sentence, so I examined the literature. There are hundreds of Drosophila publications that mention the ryanodine receptor in some way, but they are not about gene expression . As stated, the sentence might depend on what the authors mean by "systematic analyses." Two early works are relevant here: the Hasan and Rosbash, 1992 paper and the Sullivan et al., 2000 paper. Both are cited in this study. And both of these early papers addressed RyR gene expression, so that fact should be acknowledged up front.*

We agree with the Reviewer that there is a large number of publications that mention Drosophila ryanodine receptor with two of them identified by the Reviewer that provide information about Drosophila RyR expression. We refer to both of them and follow Reviewer’s suggestion to further acknowledge their work. The modified sentence in the text reads as follow:

“…in spite of early works by Hasan and Rosbash (1992) and Sullivan et al., (2000) no systematic analyses have yet been performed to assess the developmental expression pattern of the sole Drosophila dRyR gene…”

Concerning “systematic analyses” we mean the analyses of dRyR expression at both transcripts and protein levels during embryonic development and in differentiated muscles.

> *(2) (Related) I examined those two early papers to cross-check the extent of analysis done previously. The text of Hasan and Rosbash reports in situ examination of RyR transcript using a digoxigenin probe (though the online version of that 1992 paper seems to have left out the relevant mesodermal and muscle images referenced in the paper, in favor of duplicating Figure 5 three times - I emailed Development to alert them). More relevant, several experiments executed in the Sullivan paper agrees closely with the current paper. As such, it needs more complete referencing. The Sullivan paper showed short, round larvae in mutants (Fig. 1 of Sullivan); ubiquitous mRNA, strongly in muscle and mesoderm (Fig. 2 of Sullivan); impaired muscle function in mutants (Fig. 3 of Sullivan), and impaired larval heart rate (Fig. 4 of Sullivan).*

Sullivan et al. paper is indeed a reference paper for Drosophila RyR. Our data are however largely novel and/or substantially extending those reported by Sullivan. Notably, we show for the first time developmental dRyR protein expression pattern in embryos and in larval filets, we also analyse dRyR isoform transcripts expression and provide for the first time embryonic muscle phenotype analyses that shed light on so far under investigated developmental function of dRyR.

We follow Reviewer’s suggestion and provide in the revised version additional citations of this work:

"…attenuation of dRyR (C57>dRyR RNAi) led to a significantly reduced larva body length (Fig. 3B, M) compared to control (Fig. 3A, Q), an observation that correlates with previously observed (Sullivan et al., 2000) reduced body size of dRyR[16] mutant larvae…".

"…our data extend previous observations of affected muscle contractility in RyR mutants (Sullivan et al., 2000)…"

"…Overall, observed dRyR loss-of-function heart phenotypes with a slow heart rate and increased arrhythmia correlate with impaired cardiac function in RyR mutant larvae (Sullivan et al., 2000)…"

> *(3) Fig. 1B-D (antibody staining): There are puzzles with this experiment. The first is with the anti-Dlg channel. Dlg is a core component of the NMJ postsynaptic density, and the antibody reveals a bright cage of Dlg around the boutons. But with the muscle images in Figure 1B, there are no boutons apparent (unless they are so far out of focus as to be invisible).*

Indeed, Dlg also stains postsynaptic NMJs at the muscle surface. On the Fig. 1B showing more internal optical sections to reveal T tubules Dlg-positive NMJs are out of focus.

> *The second question centers on the dRyR antibody. The results state, "We first tested the expression of dRYR at the protein level." This sentence appears immediately after the sentence for gene expression from point 1. Technically, this antibody will help determine protein localization, not gene expression. But more importantly, there is no supporting/verifying information about this guinea pig anti-dRYR antibody. The methods state that it was provided by Robert Scott from NIMH. But there is no accompanying citation, no information about the antigen used to raise the antibody, and no negative control (either mutant or RNAi) to show that the staining is specific. If this is a published anti dRyR antibody that already meets the standards of specificity, that should be made clear, and the citation should be given. But if not, the information and data about the production of the antibody and the testing of its quality needs to be shared.*

We apologize for this omitted citation. The anti-dRyR antibody has been previously described and its specificity tested in the article Gao et al., (2013). Corresponding author of this paper David J. Sandstrom left NIMH and anti-dRyR antibodies are currently curated by Rob Scott from Benjamin White's lab at NIMH.

He generously sent us sample of this antibody. We add this information to the Material and Methods section.

> *(4) Fig. S1: Similar to the antibody, is there a negative control probe that does not reveal this expression pattern? There are any number of probes or secondary antibodies that non-specifically label Drosophila muscles in patterns just like this.*

We are confident that the HCR probes are working properly as they reveal dRyR transcripts expression that is consistent with dRyR protein expression pattern. In parallel they show differential expression in embryos.

Author response image 3 shows the control HCR ISH experiment with a probe that detects Apterous transcripts (specific for a subset of embryonic muscles and not present in L3 larval muscles).



Author response image 3. **A comparison between Ap HCR (A, A') and dRyR Ex23 HCR (E, E') signals.**

> *Minor Comments*
>
> *(1) "Overall, observed dRYR loss-of-function heart phenotypes...are reminiscent of those associated with aging (Nishimura et al., 2010), indicating that dRyR RNAi-induced impairment of Ca2+ homeostasis contributes to cardiac aging..." The conclusion of the sentence does not logically follow from the first part. This is because the tests conducted here were on rhythm, not on calcium homeostasis and cardiac aging.*

So, the tests cannot definitively say anything about those latter phenotypes.

To answer this reviewer's coment we modify the concluding sentence as follow:

"...We hypothesize that dRyR RNAi-induced impairment of Ca2+ homeostasis could contribute to cardiac aging, for which Drosophila is a recognized model (Nishimura et al., 2011)."

> *(2) Fig. S2 (bar graph): "% of total" - Is this supposed to refer to the percentage of the total muscle area that is positive for ATP5a staining? That should be clarified.*

We provide clarification in the Fig.S2 legend. "% of total" means the percentage of the measured muscle area that is positive for ATP5a staining".

> *(3) Fig. 3M, should say length*

Done

> *(4) Fig. 5A legend - See Sullivan; that paper concluded that RyR[16] was hypomorphic instead of null, based on RyR[16]/Df comparison to RyR[16]/RyR[16]. Intuitively, I agree; a lesion that rips out the start site would likely be null. The antibody could help with classifying the allele, depending on the part of RyR used as the antigen.*

The RyR^{16} mutants were indeed described by Sullivan et al., as hypomorphic and not null. In the Fig. 5 legend we modify the comment to: "...homozygous $dRyR^{16}$ mutant embryo..."

> *(5) Discussion: "This also suggests that all dRyR isoforms are collectively required for larval muscle function." That sentence does not logically follow the expression information. In order to test that idea, individual isoforms would need to be eliminated or knocked down.*

We agree with this comment and modify our sentence accordingly.

"However, whether all dRyR isoforms are collectively required for larval muscle function requires further investigation."

> ***Reviewer #3 (Significance):***
>
> *The idea that RyR is expressed in many kinds of muscle is put forth as a major conclusion. It is good that the authors report this fact, and the impacts on muscle*

> *development documented in Figure 5 are some of the best data in the paper. However, in terms of opening up a new understanding of RyR biology, the impact of this information seems modest. Prior Drosophila work and the work of others studying these channels show that ryanodine receptors are ubiquitous. The fact that there is only one Drosophila RyR gene would lead most scientists to hypothesize that it would be present on the ER surfaces of all kinds of tissues, including different types of muscle.Novel phenotypic information for Drosophila RyR is reported in the study, and this is good. But in terms of the model system, the strength of Drosophila is in using genetic combinations to make refined conclusions. That toolkit is not fully used here; therefore, the paper is mostly descriptive. This study is mostly a single-gene study (dRyR), with isolated exceptions, like Cam knockdown in Figure 5.*

To improve the functional/mechanistic aspect of the manuscript in the revised version we include to Fig.5 the analysis of myogenic role of additional calcium regulator: ER calcium pump SERCA.

https://doi.org/10.7554/eLife.111053.1.sa0